Effect of interfraction interval in hyperfractionated radiotherapy with or without concurrent chemotherapy for Stage III nonsmall cell lung cancer

被引:20
|
作者
Jeremic, B
Shibamoto, Y
机构
[1] KYOTO UNIV, CHEST DIS RES INST, DEPT ONCOL, KYOTO 60601, JAPAN
[2] UNIV HOSP, DEPT ONCOL, KRAGUJEVAC, YUGOSLAVIA
关键词
radiotherapy; hyperfractionation; interfraction interval; nonsmall cell lung cancer;
D O I
10.1016/0360-3016(95)02158-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To explore the influence of interfraction interval in hyperfractionated radiotherapy (HFX RT) with or without concurrent chemotherapy for Stage III nonsmall cell lung cancer. Methods and Materials: One hundred sixty-nine patients treated in a randomized study were retrospectively analyzed. Group I patients were treated by HFX RT with 1.2 Gy twice daily with a total dose of 64.8 Gy in 27 treatment days, while Groups II and III patients were treated by the same HFX RT and concurrent chemotherapy with carboplatin and etoposide (every week in Group II and every other week in Group III). Interfraction intervals of either 4.5-5 h or 5.5-6 h were used for each patient. Results: Patients treated with shorter interfraction intervals (4.5-5 h) had a better prognosis than those treated with longer intervals (5.5-6 h)(median survival: 22 vs. 7 months; 5-year survival rate: 27% vs. 0%, p = 0.00000). This phenomenon was observed in all treatment groups. Patients greater than or equal to 60 years of age, with Stage IIIA disease, or with previous weight loss less than or equal to 5% were treated more often with the shorter intervals than those < 60 years, with Stage IIIB disease, or with weight loss > 5%, respectively, but in all of these subgroups of patients, the shorter intervals were associated with a better prognosis. Multivariate analysis showed that the interfraction interval was an independent prognostic factor, together with sex, age, performance status, and stage, The shorter intervals were associated with an increased incidence of acute high grade toxicity, but not with an increase in late toxicity. Conclusion: Patients treated with shorter interfraction intervals (4.5-5 h) appeared to have a better survival than those treated with longer intervals (5.5-6 h). Prospective randomized studies are warranted to further investigate the influence of interfraction interval in HFX RT.
引用
收藏
页码:303 / 308
页数:6
相关论文
共 50 条
  • [31] Definitive Radiotherapy for Stage I Nonsmall Cell Lung Cancer
    Milano, Michael T.
    Zhang, Hong
    Usuki, Kenneth Y.
    Singh, Deepinder P.
    Chen, Yuhchyau
    CANCER, 2012, 118 (22) : 5572 - 5579
  • [32] The treatment of Stage III nonsmall cell lung cancer using high dose conformal radiotherapy
    Sibley, GS
    Mundt, AJ
    Shapiro, C
    Jacobs, R
    Chen, G
    Weichselbaum, R
    Vijayakumar, S
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 33 (05): : 1001 - 1007
  • [33] A pilot study of protracted low dose cisplatin and etoposide with concurrent thoracic radiotherapy in unresectable stage III nonsmall cell lung cancer
    Blanke, C
    DeVore, R
    Shyr, Y
    Epstein, B
    Murray, M
    Hande, K
    Stewart, S
    Johnson, D
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1997, 37 (01): : 111 - 116
  • [34] Hyperfractionated radiation therapy with or without concurrent chemotherapy in stage III non-small cell lung cancer (NSCLC): Single-institution experience in 600 patients
    Jeremic, B.
    Milicic, B.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (01): : S437 - S437
  • [35] FACTORS ASSOCIATED WITH SEVERE ACUTE ESOPHAGITIS FROM HYPERFRACTIONATED RADIOTHERAPY WITH CONCURRENT CHEMOTHERAPY FOR LIMITED-STAGE SMALL-CELL LUNG CANCER
    Watkins, John M.
    Wahlquist, Amy E.
    Shirai, Keisuke
    Garrett-Mayer, Elizabeth
    Aguero, Eric G.
    Fortney, John A.
    Sherman, Carol A.
    Sharma, Anand K.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 74 (04): : 1108 - 1113
  • [36] Phase 2 Study of High-Dose Proton Therapy With Concurrent Chemotherapy for Unresectable Stage III Nonsmall Cell Lung Cancer
    Chang, Joe Y.
    Komaki, Ritsuko
    Lu, Charles
    Wen, Hong Y.
    Allen, Pamela K.
    Tsao, Anne
    Gillin, Michael
    Mohan, Radhe
    Cox, James D.
    CANCER, 2011, 117 (20) : 4707 - 4713
  • [37] Imaging for staging stage III nonsmall cell lung cancer
    Vansteenkiste, J.
    Dooms, C.
    Becker, H.
    De Leyn, P.
    BREATHE, 2007, 4 (01) : 47 - 55
  • [38] Role of immunotherapy in stage III nonsmall cell lung cancer
    Wrona, Anna
    CURRENT OPINION IN ONCOLOGY, 2019, 31 (01) : 18 - 23
  • [39] Curative effect of hyperfractionated accelerated radiotherapy combined with EP chemotherapy regimen on limited-stage small cell lung cancer
    Tan, Yeru
    Yang, Qiao
    Wu, Xiaoping
    Zhu, Hongbo
    JOURNAL OF BUON, 2021, 26 (03): : 837 - 843
  • [40] Preoperative hyperfractionated radiotherapy with concurrent chemotherapy in resectable esophageal cancer
    Kim, JH
    Choi, EK
    Kim, SB
    Park, SI
    Kim, DK
    Song, HY
    Jung, HY
    Min, YI
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 50 (01): : 1 - 12